Compare TWI & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | BNTC |
|---|---|---|
| Founded | 1890 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.1M | 396.3M |
| IPO Year | 1997 | 2020 |
| Metric | TWI | BNTC |
|---|---|---|
| Price | $6.82 | $9.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $12.00 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 505.9K | 125.6K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.95 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.37 | $9.26 |
| 52 Week High | $11.70 | $16.76 |
| Indicator | TWI | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 33.18 |
| Support Level | $6.40 | N/A |
| Resistance Level | $7.43 | $13.49 |
| Average True Range (ATR) | 0.24 | 0.72 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 0.00 | 16.93 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. It designs and manufactures products for OEMs and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. The company operates through three segments, namely Agricultural, Earthmoving/Construction, and Consumer. It derives the majority of revenue from the Agricultural segment which manufactures various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment. Geographically, the company generates the maximum revenue from North America, followed by Europe / CIS, Latin America, and Asia and other regions.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.